- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.02. | OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts | ||
| 04.02. | As CEO, Luke Miels wants GSK to be more 'product-centric' | ||
| 04.02. | Amgen resists FDA request to pull rare disease drug Tavneos from the market | ||
| 03.02. | India will invest $1.1B to boost development of biologics, biosimilars | ||
| 03.02. | Novo shares plummet on sales, profit warning for '26 as 2 top execs head for the doors | ||
| 03.02. | Charles River to close cell therapy CDMO site, lay off 20 staffers | ||
| 03.02. | Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade | ||
| 03.02. | FDA signals tailored approach to 'carefully shepherd' CAR-T therapy for autoimmune diseases | ||
| 03.02. | BMS, J&J factor in HCP education on clot-busting mechanism before milvexian data drop | ||
| 03.02. | FDA rejects AstraZeneca's subQ Saphnelo, but company expects quick turnaround for new approval decision | ||
| 03.02. | Sanofi sanctioned by PMCPA over CEO's 'bold claims' about Pfizer RSV vaccine | ||
| 02.02. | AbbVie has 'Love in Mind' with new migraine educational campaign | ||
| 02.02. | Thermo Fisher trims Massachusetts headcount with Franklin site closure | ||
| 02.02. | With FDA rejections, Aquestive's shares go up, while Pharming's go down | ||
| 02.02. | FDA emphasizes drug ingredients, production pledges as it debuts PreCheck manufacturing program | ||
| 02.02. | Regulatory tracker: FDA sets decision date for Summit's PD-1xVEGF bid | ||
| 30.01. | Trump administration officials are at loggerheads over future of COVID vaccines: Axios | ||
| 30.01. | CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns | ||
| 30.01. | A sales turnaround for Regeneron's Eylea franchise will have to wait at least another quarter | ||
| 30.01. | Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in PA | ||
| 30.01. | Quince Therapeutics on the brink as steroid-in-blood-cell fails in rare genetic disease | ||
| 29.01. | Novo gets Chamber of Commerce backing in bid to bring IRA challenge to Supreme Court | ||
| 29.01. | Hims & Hers uses another Super Bowl ad to tackle healthcare affordability | ||
| 29.01. | Takeda, still in a Vyvanse slog, lifts guidance as it looks to new wave of growth | ||
| 29.01. | ARS Pharma TV ad for epinephrine nasal spray Neffy needled by FDA in untitled letter |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.